Innate Pharma (IPHYF) Downgraded by Zacks Investment Research

Innate Pharma (OTCMKTS:IPHYF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, March 16th.

According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “

How to Become a New Pot Stock Millionaire

OTCMKTS IPHYF traded up $0.34 on Friday, reaching $8.00. The stock had a trading volume of 500 shares, compared to its average volume of 609. Innate Pharma has a 1 year low of $4.92 and a 1 year high of $13.71.

ILLEGAL ACTIVITY WARNING: “Innate Pharma (IPHYF) Downgraded by Zacks Investment Research” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/innate-pharma-iphyf-lowered-to-sell-at-zacks-investment-research.html.

About Innate Pharma

Innate Pharma SA, a clinical-stage biotechnology company, discovers, develops, and sells immunotherapies for cancer and inflammatory diseases in France. The company offers Lirilumab (IPH2102/BMS-986015), a human checkpoint inhibitor, which is in Phase I/II clinical trial for squamous cell carcinoma of the head and neck, as well as in Phase I and Phase II clinical trials in various combinations to treat solid and hematologic tumors; Monalizumab, an immune checkpoint inhibitor that is in Phase I/II clinical trial to treat various cancer indications, as well as in Phase I clinical trial for the treatment of solid tumors; and IPH4102, an anti-KIR3DL2 humanized antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas.

Get a free copy of the Zacks research report on Innate Pharma (IPHYF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply